Relationship between the gastrointestinal side effects of an anti-hypertensive medication and changes in the serum lipid metabolome

Yoomin Ahn; Myung Hee Nam; Eungbin Kim

doi:10.3390/nu12010205

Relationship between the gastrointestinal side effects of an anti-hypertensive medication and changes in the serum lipid metabolome

Yoomin Ahn, Myung Hee Nam, Eungbin Kim

Department of Systems Biology

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

An earlier study using a rat model system indicated that the active ingredients contained in the anti-hypertensive medication amlodipine (AMD) appeared to induce various bowel problems, including constipation and inflammation. A probiotic blend was found to alleviate intestinal complications caused by the medicine. To gain more extensive insight into the beneficial effects of the probiotic blend, we investigated the changes in metabolite levels using a non-targeted metabolic approach with ultra-performance liquid chromatography-quadrupole/time-of-fligh (UPLC-q/TOF) mass spectrometry. Analysis of lipid metabolites revealed that rats that received AMD had a different metabolome profile compared with control rats and rats that received AMD plus the probiotic blend. In the AMD-administered group, serum levels of phosphatidylcholines, lysophosphatidylcholines, sphingomyelins, triglycerides with large numbers of double bonds, cholesterols, sterol derivatives, and cholesterol esters (all p < 0.05) were increased compared with those of the control group and the group that received AMD plus the probiotic blend. The AMD-administered group also exhibited significantly decreased levels of triglycerides with small numbers of double bonds (all p < 0.05). These results support our hypothesis that AMD-induced compositional changes in the gut microbiota are a causal factor in inflammation.

Original language	English
Article number	205
Journal	Nutrients
Volume	12
Issue number	1
DOIs	https://doi.org/10.3390/nu12010205
Publication status	Published - 2020 Jan

Bibliographical note

Funding Information:
Funding: This research was financially supported in part by Cell Biotech Co., Ltd. through the Cell Biotech R&D Centre and in part by the Strategic Initiative for Microbiomes in Agriculture and Food (918011‐4) funded by the Ministry of Agriculture, Food and Rural Affairs. M.N. acknowledges the financial support from the National Research Foundation of Korea (NRF‐2018M3A9F3056901).

Funding Information:
This research was financially supported in part by Cell Biotech Co., Ltd. through the Cell Biotech R&D Centre and in part by the Strategic Initiative for Microbiomes in Agriculture and Food (918011-4) funded by the Ministry of Agriculture, Food and Rural Affairs. M.N. acknowledges the financial support from the National Research Foundation of Korea (NRF-2018M3A9F3056901).

Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.

All Science Journal Classification (ASJC) codes

Food Science
Nutrition and Dietetics

Access to Document

10.3390/nu12010205

Cite this

@article{16545e6916e14493909a8388b4567672,

title = "Relationship between the gastrointestinal side effects of an anti-hypertensive medication and changes in the serum lipid metabolome",

abstract = "An earlier study using a rat model system indicated that the active ingredients contained in the anti-hypertensive medication amlodipine (AMD) appeared to induce various bowel problems, including constipation and inflammation. A probiotic blend was found to alleviate intestinal complications caused by the medicine. To gain more extensive insight into the beneficial effects of the probiotic blend, we investigated the changes in metabolite levels using a non-targeted metabolic approach with ultra-performance liquid chromatography-quadrupole/time-of-fligh (UPLC-q/TOF) mass spectrometry. Analysis of lipid metabolites revealed that rats that received AMD had a different metabolome profile compared with control rats and rats that received AMD plus the probiotic blend. In the AMD-administered group, serum levels of phosphatidylcholines, lysophosphatidylcholines, sphingomyelins, triglycerides with large numbers of double bonds, cholesterols, sterol derivatives, and cholesterol esters (all p < 0.05) were increased compared with those of the control group and the group that received AMD plus the probiotic blend. The AMD-administered group also exhibited significantly decreased levels of triglycerides with small numbers of double bonds (all p < 0.05). These results support our hypothesis that AMD-induced compositional changes in the gut microbiota are a causal factor in inflammation.",

author = "Yoomin Ahn and Nam, {Myung Hee} and Eungbin Kim",

note = "Funding Information: Funding: This research was financially supported in part by Cell Biotech Co., Ltd. through the Cell Biotech R&D Centre and in part by the Strategic Initiative for Microbiomes in Agriculture and Food (918011‐4) funded by the Ministry of Agriculture, Food and Rural Affairs. M.N. acknowledges the financial support from the National Research Foundation of Korea (NRF‐2018M3A9F3056901). Funding Information: This research was financially supported in part by Cell Biotech Co., Ltd. through the Cell Biotech R&D Centre and in part by the Strategic Initiative for Microbiomes in Agriculture and Food (918011-4) funded by the Ministry of Agriculture, Food and Rural Affairs. M.N. acknowledges the financial support from the National Research Foundation of Korea (NRF-2018M3A9F3056901). Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2020",

month = jan,

doi = "10.3390/nu12010205",

language = "English",

volume = "12",

journal = "Nutrients",

issn = "2072-6643",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "1",

}

TY - JOUR

T1 - Relationship between the gastrointestinal side effects of an anti-hypertensive medication and changes in the serum lipid metabolome

AU - Ahn, Yoomin

AU - Nam, Myung Hee

AU - Kim, Eungbin

N1 - Funding Information: Funding: This research was financially supported in part by Cell Biotech Co., Ltd. through the Cell Biotech R&D Centre and in part by the Strategic Initiative for Microbiomes in Agriculture and Food (918011‐4) funded by the Ministry of Agriculture, Food and Rural Affairs. M.N. acknowledges the financial support from the National Research Foundation of Korea (NRF‐2018M3A9F3056901). Funding Information: This research was financially supported in part by Cell Biotech Co., Ltd. through the Cell Biotech R&D Centre and in part by the Strategic Initiative for Microbiomes in Agriculture and Food (918011-4) funded by the Ministry of Agriculture, Food and Rural Affairs. M.N. acknowledges the financial support from the National Research Foundation of Korea (NRF-2018M3A9F3056901). Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2020/1

Y1 - 2020/1

N2 - An earlier study using a rat model system indicated that the active ingredients contained in the anti-hypertensive medication amlodipine (AMD) appeared to induce various bowel problems, including constipation and inflammation. A probiotic blend was found to alleviate intestinal complications caused by the medicine. To gain more extensive insight into the beneficial effects of the probiotic blend, we investigated the changes in metabolite levels using a non-targeted metabolic approach with ultra-performance liquid chromatography-quadrupole/time-of-fligh (UPLC-q/TOF) mass spectrometry. Analysis of lipid metabolites revealed that rats that received AMD had a different metabolome profile compared with control rats and rats that received AMD plus the probiotic blend. In the AMD-administered group, serum levels of phosphatidylcholines, lysophosphatidylcholines, sphingomyelins, triglycerides with large numbers of double bonds, cholesterols, sterol derivatives, and cholesterol esters (all p < 0.05) were increased compared with those of the control group and the group that received AMD plus the probiotic blend. The AMD-administered group also exhibited significantly decreased levels of triglycerides with small numbers of double bonds (all p < 0.05). These results support our hypothesis that AMD-induced compositional changes in the gut microbiota are a causal factor in inflammation.

AB - An earlier study using a rat model system indicated that the active ingredients contained in the anti-hypertensive medication amlodipine (AMD) appeared to induce various bowel problems, including constipation and inflammation. A probiotic blend was found to alleviate intestinal complications caused by the medicine. To gain more extensive insight into the beneficial effects of the probiotic blend, we investigated the changes in metabolite levels using a non-targeted metabolic approach with ultra-performance liquid chromatography-quadrupole/time-of-fligh (UPLC-q/TOF) mass spectrometry. Analysis of lipid metabolites revealed that rats that received AMD had a different metabolome profile compared with control rats and rats that received AMD plus the probiotic blend. In the AMD-administered group, serum levels of phosphatidylcholines, lysophosphatidylcholines, sphingomyelins, triglycerides with large numbers of double bonds, cholesterols, sterol derivatives, and cholesterol esters (all p < 0.05) were increased compared with those of the control group and the group that received AMD plus the probiotic blend. The AMD-administered group also exhibited significantly decreased levels of triglycerides with small numbers of double bonds (all p < 0.05). These results support our hypothesis that AMD-induced compositional changes in the gut microbiota are a causal factor in inflammation.

UR - http://www.scopus.com/inward/record.url?scp=85077941641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077941641&partnerID=8YFLogxK

U2 - 10.3390/nu12010205

DO - 10.3390/nu12010205

M3 - Article

C2 - 31941114

AN - SCOPUS:85077941641

SN - 2072-6643

VL - 12

JO - Nutrients

JF - Nutrients

IS - 1

M1 - 205

ER -

Relationship between the gastrointestinal side effects of an anti-hypertensive medication and changes in the serum lipid metabolome

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this